Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (PBH): 46 pipeline candidates · 87 upcoming catalysts. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
N/A
D/E 0.85
Lead: Approved
46 candidates
87 upcoming, next in ~9d
0 buys · 5 sells (180d)
A transparent, data-derived signal for Prestige Consumer Healthcare Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.2B
Cash
$63.9M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (46 candidates)
| Drug | Phase |
|---|---|
| acetazolamide | Approved |
| aliskiren | Approved |
| aspirin | Approved |
| benztropine | Approved |
| bismuth sub | Approved |
| buprenorphine | Approved |
| bupropion | Approved |
| calcitonin-salmon | Approved |
| chlorzoxazone | Approved |
| ciprofloxacin | Approved |
Showing 10 of 46 candidates. Sign up for full pipeline.
Upcoming Catalysts (87)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
350
Total value held
$3.04B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,388,490 | $437.9M |
| ariel investments, llc | 4,274,326 | $253.3M |
| vanguard capital management llc | 4,185,986 | $248.1M |
| vanguard portfolio management llc | 2,803,828 | $166.2M |
| dimensional fund advisors lp | 2,672,777 | $158.4M |
| kayne anderson rudnick investment management llc | 2,202,606 | $130.5M |
| state street corp | 1,970,981 | $116.8M |
| geode capital management, llc | 1,460,035 | $86.5M |
| morgan stanley | 1,357,470 | $80.5M |
| westwood holdings group inc | 1,119,715 | $66.4M |
Showing top 10 of 350 institutional holders of Prestige Consumer Healthcare Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Prestige Consumer Healthcare Inc.'s pipeline?
Prestige Consumer Healthcare Inc. (PBH) has 46 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Prestige Consumer Healthcare Inc.'s lead drug candidate?
Prestige Consumer Healthcare Inc.'s most advanced tracked candidate is acetazolamide (Approved) for INDICATIONS AND USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attem.
What is Prestige Consumer Healthcare Inc.'s next catalyst?
Prestige Consumer Healthcare Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: APLENZIN" — expected June 27, 2026.
What is Prestige Consumer Healthcare Inc.'s market capitalization?
Prestige Consumer Healthcare Inc.'s market capitalization is approximately $2.2B.
Who is the CEO of Prestige Consumer Healthcare Inc.?
Mr. Ronald M. Lombardi CPA is the chief executive officer of Prestige Consumer Healthcare Inc. (PBH).
Get the full picture on Prestige Consumer Healthcare Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.